Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates
Provided By GlobeNewswire
Last update: May 13, 2025
UNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA in December 2024 as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma
Read more at globenewswire.com
